A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer.

Trial Profile

A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Dociparstat sodium (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms PGPC1
  • Sponsors Cantex Pharmaceuticals
  • Most Recent Events

    • 24 Aug 2016 Status changed from recruiting to completed.
    • 26 Jan 2013 Interim results from the initial run in-phase (n=10) presented at the 2013 Gastrointestinal Cancers Symposium.
    • 09 Nov 2012 Planned end date changed from 1 Nov 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top